Eric Souied Joins SeaBeLife

French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee

1

Professor Eric Souied has joined SeaBeLife's scientific committee to advance its dual-pathway strategy targeting retinal degeneration.
2

Souied will guide the company's ophthalmology program, focusing on inhibiting necroptosis and ferroptosis in retinal diseases.
3

SeaBeLife claims its platform uniquely addresses both necroptosis and ferroptosis mechanisms in tandem.
4

Souied has authored over 650 publications and identified the first genetic polymorphism linked to age-related macular degeneration.
5

SeaBeLife's lead candidate, SBL03, shows preclinical efficacy in geographic atrophy, affecting an estimated eight million people globally.

1